Medicine
Eltrombopag 25 mg tablet
Eltrombopag 25 mg tablet is a generic prescription medicine for oral use, made by 13 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Eltrombopag
- Brand
- Sold under the generic name
- Strength
- 25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 84 tablets and 13 more
- Manufacturers
- BioconIndiaZydus LifesciencesIndiaCamber PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaNovadoz PharmaceuticalsIndiaAmneal Pharmaceuticals NYAmerisynAvKAREHikma PharmaceuticalsQuallent Pharmaceuticals Health
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B02BX05 Eltrombopag
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 May 2025
- Identifiers
- RxCUI 825421, 825427, 884617 +1DailyMed set ID 1cfdd1fa-d687-41f9-a160-9491f0beac1e, 52ba8e06-aa7d-caa6-e063-6294a90a5ce5, e5fd3114-56b8-3ae3-fb03-9820a26ca4c6 +12NDC 70710-1396, 87564-033, 43598-730 +12Application ANDA216281, ANDA219638, ANDA219121 +6
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle | 70710-1396-3 | Zydus LifesciencesIndia | 14 January 2026 |
| 30 tablet in 1 bottle | 70771-1926-3 | Zydus LifesciencesIndia | 14 January 2026 |
| 30 tablet, film coated in 1 bottle | 70377-184-11 | BioconIndia | 9 September 2026 |
| 84 tablet, film coated in 1 bottle | 70377-184-12 | BioconIndia | 9 September 2026 |
| 30 tablet, film coated in 1 bottle | 31722-842-30 | Camber PharmaceuticalsIndia | 13 May 2025 |
| 30 tablet, film coated in 1 bottle | 43598-730-30 | Dr. Reddy's LaboratoriesIndia | 17 March 2026 |
| 30 tablet, film coated in 1 bottle | 72205-157-30 | Novadoz PharmaceuticalsIndia | 14 January 2026 |
| 30 tablet, film coated in 1 bottle, plastic | 60219-1416-3 | Amneal Pharmaceuticals NY | 15 January 2026 |
| 30 tablet, film coated in 1 bottle | 69238-1416-3 | Amneal Pharmaceuticals NY | 15 January 2026 |
| 30 tablet, film coated in 1 bottle | 87564-033-30 | Amerisyn | 30 June 2026 |
| 30 tablet in 1 bottle | 0054-0963-13 | Hikma Pharmaceuticals | 24 April 2026 |
| 30 tablet, film coated in 1 bottle | 70069-838-01 | Somerset Therapeutics | 14 January 2026 |
| 30 tablet, film coated in 1 bottle | 0480-4210-56 | Teva Pharmaceuticals | 17 September 2026 |
| 30 tablet, film coated in 1 bottle | 72865-300-30 | XLCare Pharmaceuticals | 7 August 2025 |
| 30 tablet, film coated in 1 bottle | 42291-933-30 | AvKARE | 16 February 2026 |
| 30 tablet, film coated in 1 bottle | 82009-199-30 | Quallent Pharmaceuticals Health | 15 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Eltrombopag 25 mg tablet.
Other strengths and forms of Eltrombopag
Clinical summary
Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids. MedsAcross supplies Eltrombopag for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EltrombopagFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PROMACTA prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Revolade: European public assessment report (EPAR) · European Medicines Agency
- Eltrombopag Accord: European public assessment report (EPAR) · European Medicines Agency
Need Eltrombopag 25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.